Chambers Research is conducted by 200 Research Analysts, across 200 jurisdictions and provides nearly 6,000 rankings tables. Annually we collect hundreds of thousands of responses from clients, the majority via in-depth interview. Learn more about our methodology.
Draws from a pool of established venture capital specialists to advise private equity sponsors, investment funds and emerging companies operating in the technology and life sciences arenas. Ably assists with initial fund-raisings and all series financings. Buyouts practice demonstrates proficiency in mid-market investments and exit transactions. Extensive network of offices across the USA facilitates cross-border strength.
Clients report: "They're very good people who are very user-friendly, experienced and know where the market is."
Another client says that "it's a really strong team" and highlights the lawyers as being "super smart and commercial."
"Goodwin are very professional and give expert advice, and are always very pleasant and polite,"says a source.
Advised Bregal Sagemount on the sale of OT Topco.
Represented Y Combinator in connection with a Series F investment of £113 million into Monzo Bank.
Ali Ramadan maintains a broad transactional practice, of which venture capital investment is an area of particular strength. He acts for companies and investors from across the technology and life sciences spaces.
"Ali is very responsive and one of the rare lawyers who simply gets it. He is able to seamlessly give legal, pragmatic and commercial advice at the same time.""He is an experienced yet understated lawyer. Clients can trust Ali to be proactive and hands-on."
David Mardle maintains a destination practice for emerging technology and life sciences companies in their transactional matters. He also offers premier advice to investor clients on financings and M&A.
James Grimwood is deeply knowledgeable in a number of private equity deals, including M&A, buyouts and strategic investments, among others. His practice offers diverse sector expertise and is global in scope.
Richard Lever has an excellent track record of handling domestic and cross-border private equity deals. He represents private equity houses, corporates and management teams operating in a diverse spread of sectors.
"He has really good deal judgement, is available and gets on with it."
Sophie McGrath concentrates her practice on the representation of investors and emerging companies in an array of venture capital matters. She is particularly focused on the life sciences and technology spaces.
"Sophie is a sharp operator who is always diligent and prepared."
This content is provided by Goodwin.
In the face of a competitive marketplace, elite private equity firms expect counsel with extensive experience and a stable of blue chip relationships. That’s why private equity firms have been entrusting their deals to Goodwin. We believe our position to be unique within BigLaw given the collaboration of our private equity team with our robust life sciences, technology and healthcare practices. With our largest and strongest practices working together, Goodwin is exceptionally suited to address whatever the future brings.
Our Private Equity team is a market leader in the expansive middle market sector, having earned a reputation for notable buyouts, growth equity deals and growth company representations in key sectors such as technology, healthcare, financial and business services, consumer and manufacturing. And with the breakneck pace of technology disrupting industries around the world, we are uniquely positioned to partner with our clients and embrace the promise and potential of innovation.
Our exceptional market insights and industry relationships help our clients secure deals and build equity value. Our lawyers represent early through late stage investors and companies, lenders and financial institutions, covering the full life cycle of their investments and financings – including growth equity, add-on acquisitions, re-financings, dividend recaps, leveraged buyouts and exits, and privacy and cybersecurity matters.